Zealand Pharma completes a successful accelerated bookbuilding offering of DKK 1.5 billion

Zealand Pharma has launched and completed a successful private placement of new shares at a price of DKK 228 per share, raising gross proceeds of approximately DKK 1.5 billion. Plesner is proud to have assisted our long-time client, Zealand Pharma, with the important milestone equity raise.

Zealand Pharma has prepared a listing prospectus in connection with the offering. 

The proceeds enable Zealand to support its remaining late-stage rare disease assets, and pursue a strong strategic partner for future commercialization, advance its clinical-stage candidates, including the obesity/metabolic disease portfolio, progress additional peptide candidates from non-clinical development into early clinical development and continue its early discovery and research to develop additional peptide candidates.

Plesner acted as legal advisor to Zealand Pharma in connection with the accelerated bookbuilding offering, Cooley LLP acted as U.S. legal advisor to the company in respect of U.S. law matters. Danske Bank A/S, Goldman Sachs International, Jefferies GmbH and Nordea Danmark, Filial af Nordea Bank Abp, Finland acted as joint global coordinators and joint bookrunners and Kempen & Co. acted as co-lead manager.

Zealand Pharma is a Danish biotechnology company founded in 1998. The company is listed on Nasdaq Copenhagen and is focused on the discovery, development, and design of innovative peptide-based pharmaceuticals.

Plesner's core team consisted of Thomas Holst Laursen, Micha Fritzen, Mikkel Rostock-Jensen, Sofie Riisgaard Mathiesen and Simon Nybo Holgersen.